The communication and engagement campaign of the Alfasigma hackathon at the public relations festival
“Looking after people so as they can live up to one hundred years” are the words of Marino Golinelli who today also exceeds this goal and reaches another: 101!
Chief Executive Officer of Alfasigma, Pier Vincenzo Colli, has decided to leave the company by the end of October; at the same time, the company announces that Francesco Balestrieri will be appointed Chief Executive Officer. This change will be effective starting from 1° November 2021.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
Nutraceuticals & Medical foods
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.
Serving the medical-scientific community
doctorAsyou provides physicians and researchers with easier and smarter access to the most relevant EBM (Evidence Based Medicine) topics.
The doctorAsyou search engine is updated daily and returns over 30 million abstracts, combining the three most authoritative databases in the world: Pubmed, ICRTP, Clinicaltrials.gov
lf you’re searching for a scientific article, a paper, an abstract or more, try to use it directly from this search bar.